BioSpace News Archive

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), today announced the appointment of Isabelle Dussault, Ph.D. as senior vice president, research.

Danaher Corporation announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Goldman Sachs Global Healthcare Conference on Tuesday, June 8, 2021 at 2:10 p.m. ET.

NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), today announced that it will host a virtual KOL event for analysts, investors, and the scientific community on Friday, June 11, 2021

San Francisco, California--(Newsfile Corp. - June 7, 2021) - To view the full announcement, including downloadable images, bios, and more, click here.

Celsion Corporation announced that its 2021 Annual Meeting of Stockholders, originally scheduled for Friday, June 4, 2021 at 10:00 a.m., and adjourned to Friday, June 4, 2021 at 4:00 p.m., was convened and adjourned without any business being conducted due to a quorum not being present to conduct the meeting.

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High or Mis-match Repair-Deficient Solid Tumors.

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, joined state and local officials, fellow tenants, and community partners, in a groundbreaking ceremony for 101 College Street, a new 525,000-square-foot-building to be constructed as part of New Haven’s Downtown Crossing revitalization project.

Biofacturing leader Zymergen today announced the company will be participating in the upcoming Goldman Sachs Annual Global Healthcare Virtual Conference.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health,” the “Company” or the “Offeror”) announced today the results to date of its pending cash tender offer (the “Tender Offer”), to purchase any and all of its outstanding 7.00% Senior Secured Notes due 2024 (the “Notes”), as well as the anticipated early settlement date for the Tender Offer on June 8, 2021 (the “Early Settlement Date”).

Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), together with IASO Biotherapeutics (IASO Bio), jointly announced to deliver an oral presentation on updated data from the Phase I study of IBI326 in patients with relapsed/refractory multiple myeloma (R/R MM) at the European Hematology Association (EHA) Congress,